Roche's Divarasib Shows Statistically Significant Progression-Free And Overall Survival Gains Versus Sotorasib Or Adagrasib In NSCLC Study

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an upcoming medical meeting